Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

FDA approves label expansion in chronic heart failure for Entresto

Feb. 17, 2021

CXCR7 as a novel therapeutic target for myocardial infarction

Feb. 17, 2021

BioCardia announces pipeline updates and milestones

Feb. 3, 2021

PERK inhibition promising for pulmonary arterial hypertension

Feb. 1, 2021

5-HT2B as a novel therapeutic target to improve microstructural remodeling post-MI

Jan. 26, 2021

MCB-613 attenuates loss of cardiac function after myocardial infarction

Jan. 21, 2021

FDA approves Verquvo for heart failure

Jan. 20, 2021

Caladrius opens phase IIb trial of CLBS-16 for coronary microvascular dysfunction

Jan. 20, 2021

LCP2 is a therapeutic target in lethal sepsis

Jan. 19, 2021

Apabetalone protects from heart failure in patients with T2D and ACS

Jan. 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...